Skip to main content
. 2016 Dec 24;19(1):i1–i24. doi: 10.1093/neuonc/now197

Fig. 2.

Fig. 2.

Non–small cell lung cancer mutations.

Although more than one-third of driver mutations in non–small cell lung cancer (NSCLC) are still unknown, approximately one-half of primary single mutations have been identified. The approval of targeted therapies for epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinomas has led to a better understanding of individual driver and resistance mutations upon tumor progression.17 , 18 (Large pie chart adapted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.17 , 18)